NovaBay Pharmaceuticals (NBY) Competitors $0.69 -0.02 (-3.10%) (As of 01:50 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends NBY vs. AIM, SLGL, NLSP, WENA, SNSE, NKGN, AWH, TLPH, TSBX, and CDTShould you be buying NovaBay Pharmaceuticals stock or one of its competitors? The main competitors of NovaBay Pharmaceuticals include AIM ImmunoTech (AIM), Sol-Gel Technologies (SLGL), NLS Pharmaceutics (NLSP), ANEW Medical (WENA), Sensei Biotherapeutics (SNSE), NKGen Biotech (NKGN), Aspira Women's Health (AWH), Talphera (TLPH), Turnstone Biologics (TSBX), and Conduit Pharmaceuticals (CDT). These companies are all part of the "pharmaceutical products" industry. NovaBay Pharmaceuticals vs. AIM ImmunoTech Sol-Gel Technologies NLS Pharmaceutics ANEW Medical Sensei Biotherapeutics NKGen Biotech Aspira Women's Health Talphera Turnstone Biologics Conduit Pharmaceuticals NovaBay Pharmaceuticals (NYSE:NBY) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations. Which has more volatility and risk, NBY or AIM? NovaBay Pharmaceuticals has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.36, indicating that its share price is 136% less volatile than the S&P 500. Which has better valuation and earnings, NBY or AIM? NovaBay Pharmaceuticals has higher revenue and earnings than AIM ImmunoTech. AIM ImmunoTech is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovaBay Pharmaceuticals$14.73M0.23-$9.64M-$53.72-0.01AIM ImmunoTech$200K67.05-$28.96M-$0.47-0.45 Do analysts prefer NBY or AIM? NovaBay Pharmaceuticals currently has a consensus target price of $0.85, indicating a potential upside of 23.73%. AIM ImmunoTech has a consensus target price of $3.00, indicating a potential upside of 1,325.18%. Given AIM ImmunoTech's higher probable upside, analysts clearly believe AIM ImmunoTech is more favorable than NovaBay Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NovaBay Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00AIM ImmunoTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor NBY or AIM? In the previous week, AIM ImmunoTech had 12 more articles in the media than NovaBay Pharmaceuticals. MarketBeat recorded 13 mentions for AIM ImmunoTech and 1 mentions for NovaBay Pharmaceuticals. AIM ImmunoTech's average media sentiment score of 0.52 beat NovaBay Pharmaceuticals' score of 0.00 indicating that AIM ImmunoTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovaBay Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AIM ImmunoTech 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in NBY or AIM? AIM ImmunoTech received 57 more outperform votes than NovaBay Pharmaceuticals when rated by MarketBeat users. Likewise, 82.86% of users gave AIM ImmunoTech an outperform vote while only 2.22% of users gave NovaBay Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNovaBay PharmaceuticalsOutperform Votes12.22%Underperform Votes4497.78% AIM ImmunoTechOutperform Votes5882.86% Underperform Votes1217.14% Do insiders & institutionals believe in NBY or AIM? 23.3% of NovaBay Pharmaceuticals shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 0.1% of NovaBay Pharmaceuticals shares are held by insiders. Comparatively, 0.0% of AIM ImmunoTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is NBY or AIM more profitable? NovaBay Pharmaceuticals has a net margin of -102.72% compared to AIM ImmunoTech's net margin of -12,594.21%. AIM ImmunoTech's return on equity of -421.73% beat NovaBay Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NovaBay Pharmaceuticals-102.72% -7,293.78% -158.41% AIM ImmunoTech -12,594.21%-421.73%-147.54% SummaryAIM ImmunoTech beats NovaBay Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Ad Colonial Metals“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Get NovaBay Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBY vs. The Competition Export to ExcelMetricNovaBay PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3.46M$6.48B$5.07B$19.90BDividend YieldN/A8.11%4.99%3.49%P/E Ratio-0.014.9789.5636.63Price / Sales0.24371.451,224.8017.98Price / CashN/A52.5939.4521.28Price / Book3.2010.306.974.58Net Income-$9.64M$153.61M$119.04M$985.06M7 Day Performance-3.11%-1.73%-1.78%0.51%1 Month Performance13.51%-7.26%-3.59%1.13%1 Year Performance-93.56%31.10%31.64%24.80% NovaBay Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBYNovaBay Pharmaceuticals0.6949 of 5 stars$0.69-3.1%$0.85+23.7%-93.7%$3.37M$14.73M-0.0130AIMAIM ImmunoTech1.7374 of 5 stars$0.21+5.3%$3.00+1,325.2%-52.0%$13.41M$200,000.00-0.4520News CoverageSLGLSol-Gel Technologies3.6128 of 5 stars$0.48+8.3%$5.00+947.1%-68.5%$13.30M$1.55M-1.3050News CoverageGap DownNLSPNLS Pharmaceutics1.2189 of 5 stars$3.31+0.6%N/A+623.1%$12.64MN/A0.006WENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap UpSNSESensei Biotherapeutics4.8056 of 5 stars$0.48-2.8%$4.33+795.3%-20.0%$12.17MN/A0.0040News CoverageNKGNNKGen BiotechN/A$0.34+7.9%N/A-89.1%$11.94M$80,000.00-0.06N/AGap UpHigh Trading VolumeAWHAspira Women's Health1.533 of 5 stars$0.74+1.4%$4.40+494.6%-78.5%$11.88M$9.15M-0.64110Analyst ForecastTLPHTalphera2.6915 of 5 stars$0.69-2.3%$4.50+552.1%N/A$11.75M$650,000.000.0019Gap UpTSBXTurnstone Biologics3.2023 of 5 stars$0.48+4.4%$2.13+342.7%-84.8%$11.10M$19.31M0.0082CDTConduit PharmaceuticalsN/A$0.11+21.0%N/A-92.8%$10.72MN/A0.003News CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies AIM Alternatives SLGL Alternatives NLSP Alternatives WENA Alternatives SNSE Alternatives NKGN Alternatives AWH Alternatives TLPH Alternatives TSBX Alternatives CDT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:NBY) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NovaBay Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
